Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oral7 is an immunologically active saliva substitute (IASS) range of oral care products, including mouthwash, spray, gel, and toothpaste, developed to manage xerostomia (dry mouth) and radiation-induced mucositis. The formulation contains a combination of natural enzymes—lactoperoxidase, lysozyme, glucose oxidase, and lactoferrin—which are naturally occurring in human saliva and provide essential antimicrobial and protective functions. By supplementing these enzymes, Oral7 helps restore the oral microenvironment, provides long-lasting moisture, and reduces the risk of oral infections and dental caries. It is particularly indicated for patients undergoing radiotherapy for head and neck cancers (such as nasopharyngeal carcinoma), individuals with Sjögren's syndrome, and those suffering from medication-induced hyposalivation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oral7.